Sanegene Bio
SanegeneBio is a pioneering RNA interference (RNAi) therapeutics company dedicated to developing innovative gene silencing medicines. Established in 2021 and operating in both the US and China, the company leverages proprietary delivery platforms and chemical modification technologies to target a broad spectrum of diseases, including cardiovascular, metabolic, immunological, and neurological disorders. With a focus on scientific innovation, SanegeneBio aims to address unmet medical needs and improve patient outcomes worldwide.
Industries
Nr. of Employees
medium (51-250)
Sanegene Bio
Products
SGB-3908 (siRNA targeting angiotensinogen/AGT)
An siRNA candidate targeting angiotensinogen (AGT) delivered to the liver to reduce AGT and downstream angiotensin biomarkers, intended to lower blood pressure with long duration of effect.
SGB-9768 (siRNA targeting complement C3)
An siRNA therapeutic candidate designed to reduce complement C3 protein synthesis via hepatic delivery, developed for complement‑mediated diseases.
SGB-3383 (siRNA targeting complement factor B/CFB)
An siRNA candidate targeting complement factor B (CFB) delivered to the liver to reduce CFB expression for the treatment of complement‑mediated kidney and systemic diseases.
SGB-3403 (siRNA targeting PCSK9)
An siRNA candidate designed to suppress PCSK9 expression in the liver to reduce LDL‑C for treatment of hypercholesterolemia and cardiovascular risk reduction.
SGB-3908 (siRNA targeting angiotensinogen/AGT)
An siRNA candidate targeting angiotensinogen (AGT) delivered to the liver to reduce AGT and downstream angiotensin biomarkers, intended to lower blood pressure with long duration of effect.
SGB-9768 (siRNA targeting complement C3)
An siRNA therapeutic candidate designed to reduce complement C3 protein synthesis via hepatic delivery, developed for complement‑mediated diseases.
SGB-3383 (siRNA targeting complement factor B/CFB)
An siRNA candidate targeting complement factor B (CFB) delivered to the liver to reduce CFB expression for the treatment of complement‑mediated kidney and systemic diseases.
SGB-3403 (siRNA targeting PCSK9)
An siRNA candidate designed to suppress PCSK9 expression in the liver to reduce LDL‑C for treatment of hypercholesterolemia and cardiovascular risk reduction.
Services
Design and execution of in vivo pharmacology, safety, and biomarker studies across rodent and non‑human primate models to support candidate selection and IND-enabling packages.
End-to-end process development, analytical method development, process validation and GMP scale-up support for oligonucleotide drug substance and product.
Design and conduct of early‑phase clinical trials including first‑in‑human SAD/MAD studies and multicenter Phase II studies with integrated PK/PD and biomarker endpoints.
Collaborative agreements and licensing arrangements to enable partner access to delivery and chemistry platforms for co‑development, regional development and potential commercialization.
Design and execution of in vivo pharmacology, safety, and biomarker studies across rodent and non‑human primate models to support candidate selection and IND-enabling packages.
End-to-end process development, analytical method development, process validation and GMP scale-up support for oligonucleotide drug substance and product.
Design and conduct of early‑phase clinical trials including first‑in‑human SAD/MAD studies and multicenter Phase II studies with integrated PK/PD and biomarker endpoints.
Collaborative agreements and licensing arrangements to enable partner access to delivery and chemistry platforms for co‑development, regional development and potential commercialization.
Expertise Areas
- RNAi therapeutics development
- Oligonucleotide chemistry and conjugation strategies
- Hepatic and extrahepatic siRNA delivery
- Preclinical in vivo pharmacology and non‑human primate efficacy models
Key Technologies
- RNA interference (siRNA)
- GalNAc conjugation for hepatocyte targeting
- Ligand- and enhancer-assisted delivery platforms
- Oligonucleotide chemical modification chemistries
News & Updates
On Aug. 2, 2024, SanegeneBio and Innovent announced the first participant was dosed in a Phase 1 trial of SGB-3908 for hypertension.
On Aug. 6, 2024, SanegeneBio announced the first subject dosed in a Phase I trial of SGB-9768 targeting C3.
On May 20, 2025, SanegeneBio announced that SGB-9768 received clinical trial approval for treating complement-mediated kidney diseases.
Top 100 Future Medical Companies in China 2025
SanegeneBio was listed among the top 100 innovative medical companies in China in 2025.
On Aug. 2, 2024, SanegeneBio and Innovent announced the first participant was dosed in a Phase 1 trial of SGB-3908 for hypertension.
On Aug. 6, 2024, SanegeneBio announced the first subject dosed in a Phase I trial of SGB-9768 targeting C3.
On May 20, 2025, SanegeneBio announced that SGB-9768 received clinical trial approval for treating complement-mediated kidney diseases.
Top 100 Future Medical Companies in China 2025
SanegeneBio was listed among the top 100 innovative medical companies in China in 2025.